Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918122 | 0.81 | APEX1 (0.46) | NLRP3MAPTL3MBTL1APEX1ALDH1A1 | |
| SCHEMBL1991051 | 0.80 | NLRP3 (0.35) | NLRP3MAPTL3MBTL1APEX1ALDH1A1 | |
| SCHEMBL6365346 | 0.80 | ALDH1A1 (0.52) | NLRP3MAPTL3MBTL1APEX1ALDH1A1 | |
| SCHEMBL9921593 | 0.78 | NLRP3 (0.35) | NLRP3MAPTL3MBTL1 | |
| SCHEMBL22015927 | 0.77 | NLRP3 (0.33) | NLRP3MAPTL3MBTL1 | |
| SCHEMBL21626535 | 0.76 | POLB (0.41) | L3MBTL1ALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL14841644 | 0.72 | NLRP3 (0.34) | NLRP3APEX1 | |
| SCHEMBL23201536 | 0.72 | NLRP3 (0.32) | NLRP3 | |
| SCHEMBL30787950 | 0.72 | JAK2 (0.31) | NLRP3 | |
| SCHEMBL22015932 | 0.70 | ALDH1A1 (0.34) | ALDH1A1KDM4EMEN1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 824 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260097013-A1 | COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE | EPICENTRX INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4674954-A1 | TUMOR INFILTRATING LYMPHOCYTE EXPRESSING MEMBRANE-BOUND CYTOKINE | Shanghai Juncell Therapeutics Co., Ltd. (CN) | 2026-01-07 | — | — | EP | claimed |
| US-20250296966-A1 | COMBINATION OF AN ANTIBODY SPECIFIC FOR A TUMOR ANTIGEN AND A CD47 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-25 | — | — | US | claimed |
| US-20250288555-A1 | SYSTEMS AND METHODS TO IMPROVE EXERCISE TOLERANCE | EPICENTRX, INC. (US) | 2025-09-18 | — | — | US | claimed |
| EP-4595963-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE FOR INDUCING IMMUNOGENIC CELL DEATH AND USE | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-08-06 | — | — | EP | claimed |
| EP-4588485-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND TOPOISOMERASE INHIBITOR AND USE THEREOF | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-07-23 | — | — | EP | claimed |
| EP-4585227-A1 | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND EGFR-TKI, AND USE | Inxmed (Nanjing) Co., Ltd. (CN) | 2025-07-16 | — | — | EP | claimed |
| US-20210244870-A1 | MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS | EPICENTRX, INC. | 2021-08-12 | — | — | US | claimed |
| US-20210178050-A1 | MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS | EPICENTRX, INC. | 2021-06-17 | — | — | US | claimed |
| EP-3402480-B1 | COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE | EPICENTRX INC (US) | 2021-03-24 | — | — | EP | claimed |
| EP-2534131-B1 | METHODS OF SYNTHESIZING AND ISOLATING N-(BROMOACETYL)-3,3-DINITROAZETIDINE AND A COMPOSITION INCLUDING THE SAME | ALLIANT TECHSYSTEMS INC (US) | 2014-03-19 | — | — | EP | claimed |
| US-8471041-B2 | Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same | ALLIANT TECHSYSTEMS INC. (US) | 2013-06-25 | — | — | US | claimed |
| EP-2534131-A1 | METHODS OF SYNTHESIZING AND ISOLATING N-(BROMOACETYL)-3,3-DINITROAZETIDINE AND A COMPOSITION INCLUDING THE SAME | ALLIANT TECHSYSTEMS INC. (US) | 2012-12-19 | — | — | EP | claimed |
| WO-2011100090-A1 | METHODS OF SYNTHESIZING AND ISOLATING N-(BROMOACETYL)-3,3-DINITROAZETIDINE AND A COMPOSITION INCLUDING THE SAME | ALLIANT TECHSYSTEMS INC. (US) | 2011-08-18 | — | — | WO | claimed |
| US-20110195947-A1 | METHODS OF SYNTHESIZING AND ISOLATING N-(BROMOACETYL)-3,3-DINITROAZETIDINE AND A COMPOSITION INCLUDING THE SAME | ALLIANT TECHSYSTEMS INC. (US) | 2011-08-11 | — | — | US | claimed |
| US-7745643-B2 | chemical synthesizing a N-(haloacetyl)-3,3-dinitro-azetidine compound; anticarciogenic, antiinflammatory, antihypoxic, antidiabetic agent; cardiovascular and autoimmune disease; rheumatoid arthritis, diabetic retinopathy | ALLIANT TECHSYSTEMS INC. (US) | 2010-06-29 | — | — | US | claimed |
| US-20090093644-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | ALLIANT TECHSYSTEMS INC. (US) | 2009-04-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296966-A1 | COMBINATION OF AN ANTIBODY SPECIFIC FOR A TUMOR ANTIGEN AND A CD47 INHIBITOR | CD47, TSG101, TMEM205 | NLRP3 3221/4885MAPT 3410/4885L3MBTL1 3814/4885 |
| US-20250288555-A1 | SYSTEMS AND METHODS TO IMPROVE EXERCISE TOLERANCE | SPR, GYS1, PYGM | NLRP3 4445/4885MAPT 4863/4885L3MBTL1 3600/4885 |
| US-20090093644-A1 | METHODS OF SYNTHESIZING CYCLIC NITRO COMPOUNDS | NOS2, NOS1, NOS3 | NLRP3 965/4885MAPT 4169/4885L3MBTL1 3680/4885 |
| US-20260097013-A1 | COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE | HBZ, KLK3, ALG3 | NLRP3 4313/4885MAPT 4339/4885L3MBTL1 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.